全文获取类型
收费全文 | 1190篇 |
免费 | 122篇 |
国内免费 | 46篇 |
专业分类
耳鼻咽喉 | 8篇 |
儿科学 | 74篇 |
妇产科学 | 33篇 |
基础医学 | 111篇 |
口腔科学 | 36篇 |
临床医学 | 201篇 |
内科学 | 293篇 |
皮肤病学 | 28篇 |
神经病学 | 64篇 |
特种医学 | 159篇 |
外科学 | 96篇 |
综合类 | 26篇 |
一般理论 | 1篇 |
预防医学 | 67篇 |
眼科学 | 19篇 |
药学 | 59篇 |
1篇 | |
中国医学 | 9篇 |
肿瘤学 | 73篇 |
出版年
2023年 | 3篇 |
2022年 | 2篇 |
2021年 | 11篇 |
2020年 | 10篇 |
2019年 | 6篇 |
2018年 | 23篇 |
2017年 | 26篇 |
2016年 | 25篇 |
2015年 | 31篇 |
2014年 | 41篇 |
2013年 | 50篇 |
2012年 | 28篇 |
2011年 | 41篇 |
2010年 | 51篇 |
2009年 | 71篇 |
2008年 | 39篇 |
2007年 | 60篇 |
2006年 | 34篇 |
2005年 | 43篇 |
2004年 | 23篇 |
2003年 | 27篇 |
2002年 | 28篇 |
2001年 | 28篇 |
2000年 | 24篇 |
1999年 | 32篇 |
1998年 | 79篇 |
1997年 | 86篇 |
1996年 | 58篇 |
1995年 | 54篇 |
1994年 | 39篇 |
1993年 | 43篇 |
1992年 | 19篇 |
1991年 | 14篇 |
1990年 | 14篇 |
1989年 | 27篇 |
1988年 | 22篇 |
1987年 | 27篇 |
1986年 | 15篇 |
1985年 | 18篇 |
1984年 | 13篇 |
1983年 | 12篇 |
1982年 | 10篇 |
1981年 | 8篇 |
1980年 | 9篇 |
1978年 | 5篇 |
1977年 | 11篇 |
1976年 | 5篇 |
1975年 | 2篇 |
1931年 | 1篇 |
1930年 | 1篇 |
排序方式: 共有1358条查询结果,搜索用时 15 毫秒
31.
32.
33.
34.
Sonia Franciosi PhD Yaein Shim BSc Margaret Lau BCom Michael R. Hayden MB ChB PhD Blair R. Leavitt MD CM 《Movement disorders》2013,28(14):1987-1994
Treatment effect in Huntington disease (HD) clinical trials has relied on primary outcome measures such as total motor score or functional rating scales. However, these measures have limited sensitivity, particularly in pre‐ to early stages of the disease. We performed a systematic review of HD clinical studies to identify endpoints that correlate with disease severity. Using standard HD keywords and terms, we identified 749 published studies from 1993 to 2011 based on the availability of demographic, biochemical, and clinical measures. The average and variability of each measure was abstracted and stratified according to pre‐far, pre‐close, early, mild, moderate, and severe HD stages. A fixed‐effect meta‐analysis on selected variables was conducted at various disease stages. A total of 1,801 different clinical variables and treatment outcomes were identified. Unified Huntington Disease Rating Scale (UHDRS) Motor, UHDRS Independence, and Trail B showed a trend toward separation between HD stages. Other measures, such as UHDRS Apathy, Verbal Fluency, and Symbol Digit, could only distinguish between pre‐ and early stages of disease and later stages, whereas other measures showed little correlation with increasing HD stages. Using cross‐sectional data from published HD clinical trials, we have identified potential endpoints that could be used to track HD disease progression and treatment effect. Longitudinal studies, such as TRACK‐HD, are critical for assessing the value of potential markers of disease progression for use in future HD therapeutic trials. A list of variables, references used in this meta‐analysis, and database is available at http://www.cmmt.ubc.ca/research/investigators/leavitt/publications . © 2013 International Parkinson and Movement Disorder Society 相似文献
35.
Mona Jabbour MD Martin H Osmond MD CM Terry P Klassen MD MSc 《Annals of emergency medicine》1996,28(6):690-698
Study objective: To determine the effectiveness of life support courses for health care providers on the basis of one of three outcomes: (1) patient mortality and morbidity, (2) retention of knowledge or skills, and (3) change in practice behavior. Methods: English-language articles from 1975 to 1992 were identified through MEDLINE and ERIC searches, bibliographies of articles, and current abstracts. Studies were considered relevant if they included a study population of life support providers, an intervention of any of the identified life support courses, and assessment of at least one of the three listed outcomes. Relevant studies were selected and validity scores were assigned to them by agreement of two independent reviewers, using a structured form to assess validity. Data on setting, methods, participants, intervention, and outcomes were then abstracted and verified. Results: Seventeen of 67 identified studies pertaining to life support courses met the inclusion criteria. (1) All three mortality and morbidity studies indicated a positive impact, with an overall odds ratio of .28 (95% confidence interval [CI], .22 to .37). (2) No net increase in scores was found in 5 of 8 studies of retention of knowledge and in 8 of 9 studies of skills retention. Two of three studies reporting refresher activities yielded positive effects on knowledge retention. Outcomes were not significantly different between groups taught with modular or didactic techniques. (3) Studies assessing behavioral outcome were methodologically weak. Conclusion: Among providers, retention of knowledge and skills acquired by participation in support courses is poor. However, refresher activities increase knowledge retention. Modular courses are as good as lectures for learning course material. There is evidence that use of the Advanced Trauma Life Support course has decreased mortality and morbidity. Further studies of patient outcome and provider behaviors are warranted. [Jabbour M, Osmond MH, Klassen TP: Life support courses: Are they effective? Ann Emerg Med December 1996;28:690-698.] 相似文献
36.
Carlos O. Weiss MD Ravi Varadhan PhD Milo A. Puhan MD PhD Andrew Vickers PhD Karen Bandeen-Roche PhD MS Cynthia M. Boyd MD MPH David M. Kent MD CM MSc 《Journal of general internal medicine》2014,29(4):653-660
Most people with a chronic disease actually have more than one, a condition known as multimorbidity. Despite this, the evidence base to prevent adverse disease outcomes has taken a disease-specific approach. Drawing on a conference, Improving Guidelines for Multimorbid Patients, the goal of this paper is to identify challenges to the generation of evidence to support the care of people with multimorbidity and to make recommendations for improvement. We identified three broad categories of challenges: 1) challenges to defining and measuring multimorbidity; 2) challenges related to the effects of multimorbidity on study design, implementation and analysis; and 3) challenges inherent in studying heterogeneity of treatment effects in patients with differing comorbid conditions. We propose a set of recommendations for consideration by investigators and others (reviewers, editors, funding agencies, policymaking organizations) involved in the creation of evidence for this common type of person that address each of these challenges. The recommendations reflect a general approach that emphasizes broader inclusion (recruitment and retention) of patients with multimorbidity, coupled with more rigorous efforts to measure comorbidity and comorbidity burden and the influence of multimorbidity on outcomes and the effects of therapy. More rigorous examination of heterogeneity of treatment effects requires careful attention to prioritizing the most important comorbid-related questions, and also requires studies that provide greater statistical power than conventional trials have provided. Relatively modest changes in the orientation of current research along these lines can be helpful in pointing to and partially addressing selected knowledge gaps. However, producing a robust evidence base to support patient-centered decision making in complex individuals with multimorbidity, exposed to many different combinations of potentially interacting factors that can modify the risks and benefits of therapies, is likely to require a clinical research enterprise fundamentally restructured to be more fully integrated with routine clinical practice. 相似文献
37.
38.
39.
40.